Current Environment: Production

Medical Services

Specialties

Programs & Services

Languages

  • English

Education

Medical School

Yale School of Medicine

New Haven, CT

Residency

Boston Combined Residency Program (BCRP)

Boston, MA

Fellowship

Pediatric Hematolog/Oncology

Dana-Farber/Boston Children's Cancer and Blood Disorders Center

Boston, MA

Certifications

  • American Board of Pediatrics (General)

Publications

  1. Author Correction: Molecular profiling of 888 pediatric tumors informs future precision trials and data-sharing initiatives in pediatric cancer. Nat Commun. 2024 Aug 22; 15(1):7218. View Abstract

  2. Molecular profiling of 888 pediatric tumors informs future precision trials and data-sharing initiatives in pediatric cancer. Nat Commun. 2024 Jul 11; 15(1):5837. View Abstract

  3. Real-world experience with low-dose IL-2 for children and young adults with refractory chronic graft-versus-host disease. Blood Adv. 2023 08 22; 7(16):4647-4657. View Abstract

  4. Loss of heterozygosity does not occur in BRCA1/2 mutant pediatric solid and central nervous system tumors. Pediatr Blood Cancer. 2023 11; 70(11):e30643. View Abstract

  5. A single-institution pediatric and young adult interventional oncology collaborative: Novel therapeutic options for relapsed/refractory solid tumors. Cancer Med. 2023 06; 12(12):13300-13308. View Abstract

  6. Real-world experience with low-dose IL-2 for children and young adults with refractory chronic graft-versus-host disease. Blood Adv. 2023 May 24. View Abstract

  7. Clinical Targeted Next-Generation Panel Sequencing Reveals MYC Amplification Is a Poor Prognostic Factor in Osteosarcoma. JCO Precis Oncol. 2023 03; 7:e2200334. View Abstract

  8. Rare FGFR Oncogenic Alterations in Sequenced Pediatric Solid and Brain Tumors Suggest FGFR Is a Relevant Molecular Target in Childhood Cancer. JCO Precis Oncol. 2022 11; 6:e2200390. View Abstract

  9. Molecular profiling identifies targeted therapy opportunities in pediatric solid cancer. Nat Med. 2022 08; 28(8):1581-1589. View Abstract

  10. Identification of prognostic factors in childhood T-cell acute lymphoblastic leukemia: Results from DFCI ALL Consortium Protocols 05-001 and 11-001. Pediatr Blood Cancer. 2021 01; 68(1):e28719. View Abstract

  11. Making the most of small samples: Optimization of tissue allocation of pediatric solid tumors for clinical and research use. Pediatr Blood Cancer. 2020 09; 67(9):e28326. View Abstract

  12. Recurrent RET gene fusions in paediatric spindle mesenchymal neoplasms. Histopathology. 2020 Jun; 76(7):1032-1041. View Abstract

  13. Genomic and Immunologic Characterization of INI1-Deficient Pediatric Cancers. Clin Cancer Res. 2020 06 15; 26(12):2882-2890. View Abstract

  14. Precision medicine in pediatric oncology. Curr Opin Pediatr. 2018 02; 30(1):17-24. View Abstract

  15. Evaluation of SMN protein, transcript, and copy number in the biomarkers for spinal muscular atrophy (BforSMA) clinical study. PLoS One. 2012; 7(4):e33572. View Abstract

  16. Candidate proteins, metabolites and transcripts in the Biomarkers for Spinal Muscular Atrophy (BforSMA) clinical study. PLoS One. 2012; 7(4):e35462. View Abstract
BESbswy